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Abstract: Interleukin (IL-) 2 acts on a number of types of immune cells promoting their effector functions. To replace
systemic administration of recombinant form of this cytokine, various genetically modified cells have been used in
different preclinical models for tumor growth inhibition. In this study, dendritic or tumor cells transduced with retro-
viral vector carrying IL-2 gene (JAWS II/IL-2, X63/IL-2, MC38/IL-2 cells) alone or combined with tumor antigen-
stimulated dendritic cells (JAWS II/TAg) were exploited to treat colon carcinoma MC38-bearing mice. After the
peritumoral injection of vaccine cells, the tumor growth delay and the increase in the number of tumor infiltrating
CD4+ and CD8+ T lymphocytes were noted. A considerable increase in CD4+ cell influx into tumor tissue was ob-
served when JAWS II/IL-2 cells or JAWS II/TAg with syngeneic MC38/IL-2 cells were applied. The increase in
intensity of CD8+ cell infiltration was associated with immune reaction triggered by the same combination of applied
cells or JAWS II/TAg with allogeneic X63/IL-2 cells. The effect observed in vivo was accompanied by MC38/0 cell
specific cytotoxic activity of spleen cells in vitro. Thus, the application of vaccines, including IL-2-secreting cells of
various origins, was able to induce different antitumor responses polarized by exogenous IL-2 and the encountered
tumor antigen. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 3, 414–419)
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Introduction
Interleukin (IL-) 2 is a pleiotropic cytokine acting
on a number of types of immune cells to promote
their effector functions. Due to this, IL-2 has been
used as a tool in numerous clinical trials to fight
growing tumors. Because of serious side effects ob-
served after the systemic administration of IL-2,
a number of alternative forms of therapy replacing
the recombinant cytokines with genetically modified
tumors as well as immune cells have been put for-
ward [1–3]. Many studies have demonstrated that
vaccination with IL-2-secreting tumor cells can cause
considerable tumor growth inhibition, and addition-
ally induce immunological memory [3–8]. On the
other hand, results obtained in mouse models as well
as initial clinical trials have demonstrated that ge-
netically modified dendritic cells (DCs) can attend
the induction of anti-tumor immune responses fol-
lowed by tumor regression [8].
The aim of our study was to compare the effects
of the application of IL-2-transduced cells in a mod-
el of colon carcinoma MC38. The main question was
whether IL-2 transductants of various origins would
be able to support the antitumor activity of tumor
antigen (TAg)-stimulated DCs with the same efficien-
cy. The cytokine carriers were represented by synge-
neic tumor (MC38/IL-2) cells or allogeneic plasma-
cytoma (X63/IL-2) cells. Genetically modified DCs
originating from the immature dendritic cell of JAWS
II line represented immune cells.
The obtained results demonstrate that the vaccines
including particular IL-2-secreting-cells, indepen-
dently of their origin, induced similar tumor growth
delay. However, the use of IL-2-secreting-cells in com-
bination with TAg-stimulated DCs diversified their
effect on the antitumor immune response.
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Material and methods
Mice. Female C57BL/6 mice, 8–10 weeks old, were obtained
from Mossakowski Medical Research Center, Polish Acad-
emy of Sciences, Warsaw. All animal experiments were ap-
proved by the Local Ethics Committee.
Cell lines. Parental cells of the MC38/0 murine colon carcino-
ma line [9] and genetically modified cells were maintained in
RPMI 1640 supplemented with 5% fetal bovine serum (FBS).
The C57BL/6 murine bone marrow-derived DCs of the JAWS
II line (ATCC Cat. No. CRL-11904, USA), as well as cells
modified with IL-2 gene carried by retroviral vector, were cul-
tured in a culture medium containing 10% FBS and 5 ng/ml
GM-CSF (Cytogen). The X63/Ag8.653 murine plasmacyto-
ma cells transduced with IL-2 gene (Institute of Immunology
and Experimental Therapy) were maintained in culture medi-
um supplemented with 10% FBS. JAWS II cells and cells of
both murine tumor lines were transduced with retroviral vec-
tor pQN carrying murine IL-2 gene (JAWS II/IL-2, MC38/IL-2,
X63/IL-2) according to the previously described protocol [10].
Transductants produced cytokine at a relatively constant level
and were not tumorigenic (data not shown).
Therapeutic schedules. Mice were inoculated subcutane-
ously (s.c.) in the right flank with MC38/0 colon carcinoma
cells (1 × 106 cells/0.2 ml in PBS per mouse). On the 14th
day after tumor inoculation, mice with palpable nodules
were vaccinated peritumorally (p.t.) with dendritic JAWS
II/IL-2 or tumor (X63/IL-2, MC38/IL-2) cells alone or in
combination with JAWS II cells stimulated in vitro with tu-
mor antigens (JAWS II/TAg). The vaccine consisted of ca.
1 × 106 cells (when combined — 0.7 × 106 of JAWS II/TAg
cells were mixed with 0.3 × 106 of transductants). The cells
were applied once a week, for three consecutive weeks. Tu-
mor diameters were measured every 2–3 days. On the 7th
day after the last injection (35th day of the experiment), some
of the mice were sacrificed, and spleens as well as tumors
were dissected.
Tumor sections and immunohistological analysis. Tumor
tissue cryo-sections, 5–10 μm thick, were fixed in acetone
and incubated for 2 hours with rat anti-CD4 or anti-CD8
mAb (BD Pharmingen) followed by goat anti-rat antibody
conjugated with AlexaFluor488® (Molecular Probes) and
counterstained with PI. The tissue sections were analyzed
using a BioRad MRC 1024 scanning confocal fluorescence
microscope equipped with LaserSharp software. Cryosec-
tions from three distinct parts of tumor from each individu-
al mouse were analyzed.
Cytotoxicity assay of activated spleen cells. Spleen cells were
co-cultured with mitomycin C treated MC38/0 cells for
5 days. After this in vitro stimulation, spleen cell cytotoxici-
ty was investigated using a LIVE/DEAD Cell-Mediated
Cytotoxicity Kit (Molecular Probes). The cytotoxic index was
determined by the percentage of dead (PI-positive) among DiO
MC38/0 target cells. The analyses were carried out using BD
FACSCalibur apparatus with the CELLQuest software.
Results/Discussion
Our study analyzed the effect of the vaccines contain-
ing cells transduced with retroviral vector pQN carry-
ing murine IL-2 gene on the induction of antitumor
immunity. Transductants produced cytokine at the level
range 60–120 LU/ml. They were represented by non-
tumorigenic syngeneic tumor cells (MC38/IL-2 cells)
and allogeneic plasmacytoma cells (X63/IL-2 cells) and
JAWS II/IL-2 cells originating from an immature den-
dritic cell line (for detailed characteristics of these cells,
see [10]). The analysis was conducted on mice bearing
advanced murine colon carcinoma (MC38) treated
with IL-2-producing cells and/or tumor antigen-stim-
ulated dendritic (JAWS II/TAg) cells (Figure 1).
The obtained data revealed similar therapeutic ef-
fects of IL-2-producing tumor cell vaccines. The injec-
tions of MC38/IL-2 or X63/IL-2 cells elicited DTRV
(difference in the median time required for the tumor
to reach a volume of 1 cm3 compared to the control
group of mice) amounting to 5.5 or 6.5 days, and TGI
(tumor growth inhibition) amounting to 53 or 55%,
respectively. The application of JAWS II/IL-2 cells re-
sulted in stronger tumor growth delay (up to seven days
for DTRV, and TGI of 56%; see insert in Figure 1). An
explanation of their stronger effect on tumor growth
delay could be based on two activities — they could
act in a complex manner as a source of IL-2 and, to
some extent [see 10], as antigen presenting cells. This
suggests that although both tumor and dendritic vac-
cine cells were applied in the same numbers, their ther-
apeutic effects depended not only on their ability to
produce IL-2 but also on their various origins.
We noted that the application of JAWS II/TAg cells
caused tumor growth delay for only four days compared
to the control group; this is three days less than vaccine
containing the same number of JAWS II/IL-2 cells. Giv-
en this, we decided to replace the 30% of JAWS II/TAg
cells by JAWS II/IL-2 cells as well as by MC38/IL-2 or
X63/IL-2 cells. The application of JAWS II/TAg cells along
with JAWS II/IL-2 did not elicit further tumor growth
delay. Thus, JAWS II/IL-2 cells which exhibited only low
ability to present TAg [10] were not able to balance the
effect of the part of TAg-stimulated DCs and obviously
were not able to augment the vaccine’s effectiveness.
We determined which type of vaccine tumor cells
would be able to trigger efficient immunity against
advanced tumor — the syngeneic cells presenting the
same TAg as growing tumor or the allogeneic cells
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expressing antigens of distinctive MHC and represent-
ing the other type of malignancy. Based on the data
described by others, we expected that the allogeneic
IL-2-secreting transductants ought to be strong stim-
ulators inducing response not only against themselves
but also against the growing tumor. Meanwhile, the
application of vaccines consisting of JAWS II/
/TAg+MC38/IL-2 cells caused the highest tumor de-
lay (DTRV —  seven days and TGI — 61%), and af-
ter JAWS II/TAg+X63/IL-2 cell administration the
weakest effect was observed (DTRV — four days, TGI
— 40%, Figure 1). Moreover, the use of JAWS II/
/TAg+X63/IL-2 cells shortened the survival time of
mice (data not shown). Generally, it was revealed that
the application of JAWS II/IL-2 cells as well as JAWS
II/TAg+MC38/IL-2 cells affected stronger tumor
growth delay than other groups (illustrated by DTRV
amounting to seven days and TGI — to 56% and 61%,
respectively), and the use of JAWS II/TAg+X63/IL-2
cells triggered adversarial immune reaction. Overall,
tumor growth delays elicited by particular vaccines
were noted, but the differences between them were
not statistically significant. Nevertheless, our obser-
vations allow us to hypothesize that vaccines contain-
ing various type of cells elicited final results which
may be mediated by different components of the im-
mune system.
In many human cancers, the presence of T cells
infiltrating into tumor tissue is believed to be a good
prognostic marker for tumor regression [11]. The
same relationship between the number of such lym-
phocytes and their antitumor effect can be observed
Figure 1. Differences in tumor growth delay as a result of cellular vaccine application. Specific pathogen-free condition
(SPF)-female mice were injected with MC38/0 cells (1.0 × 106 cells) on day 0. Cell vaccines were applied in the vicinity of
established tumors in three consecutive weeks, starting from the 14th day. Transductants used as a component of vaccines
produced 60–120 LU of IL-2/ml/0.5 × 106 cells/48h. The main figure includes the tumor growth delay graph presented as
the median of the tumor volume (taken from five or six mice). Insert includes the median of the tumor volume (taken
from five or six mice) calculated using the Kruskal–Wallis test on the 35th day of the tumor growth. The table below
presents: *DTRV — difference in the median time required for the tumor to reach a volume of 1 cm3 compared to the
control group of mice, days; **TGI — tumor growth inhibition, %; calculated on the 35th day (seven days after the third
injection) according to the formula 100 — (MVT/MVC × 100) (%) where MVT represents the median tumor volume in
the treated mice and MVC the median tumor volume in the control mice
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in experimental tumors. In our model, the applica-
tion of dendritic and/or tumor cell vaccines induced
changes of the tumor tissue structure which were as-
sociated with the increase in the number of both CD4+
and CD8+ T cells. Generally, the influx of CD4+ cells
was more intensive than that of CD8+ cells. Howev-
er, the locations of these cells were various: CD4+
cells were found in connective tissue in tumor nod-
ules, whereas CD8+ cells were preferentially located
between tumor cells. The intensity of lymphocyte in-
flux depended on the type of vaccinated cells (Figure 2,
Table 1).
The highest infiltration of tumor tissue by both
CD4+ and CD8+ cells was observed after the injec-
tion of JAWS II/IL-2 cells. The application of
IL-2-secreting tumor cells caused a moderate influx,
higher than in the control group but comparable with
that elicited by JAWS II/TAg cells. On the other hand,
after the application of the combined cell vaccines,
a differential lymphocyte influx was noted. An inten-
Figure 2. CD4+ or CD8+ cell infiltration into tumor tissues after cell vaccine treatment. Tumors were harvested on the 35th
day. Cryo-sections, fixed in acetone, were incubated with rat anti-mouse anti-CD4 or anti-CD8 antibodies followed by goat
anti-rat antibody conjugated with AlexaFluor 488®, and counterstained with PI. The analysis of tumor infiltrating lymphocy-
tes was carried out using a scanning confocal fluorescence microscope. Magnification × 250. A: Control, B: MC38/IL-2,
C: X63/IL-2, D: JAWS II/IL-2, E: JAWS II/TAg, F: JAWS II/TAg+MC38/IL-2, G: JAWS II/TAg+X63/IL-2,
H: JAWS II/TAg+JAWS II/IL-2
A B C D
E F G H
A B C D
E F G HC
D
8+
C
D
4+
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Table 1. CD4+ or CD8+ cell infiltration into tumor tissues
after the cellular vaccine treatment
Vaccine                         Tumor infiltrating
                          lymphocytes*:
CD4+ CD8+
Control + + +
MC38/IL-2 + + + + +
X63/IL-2 + + + + +
JAWS II/IL-2 + + + + + + + +
JAWS II/TAg + + + + +
JAWS II/TAg+MC38/IL-2 + + + + + + + +
JAWS II/TAg+X63/IL-2 + + + + + +
JAWS II/TAg+JAWS II/IL-2 + + + + + +
*Intensity of CD4 and CD8 cell influx was estimated based on 4–5
representative tumor sections and is shown by the number of crosses,
i.e. “+” = few cells, and “+ + + + +” = many cells
sive influx of CD4+ cells was observed after treatment
with JAWS II/TAg+MC38/IL-2 cells, a moderate in-
flux after JAWS II/TAg+JAWS II/IL-2 cells, and
a small influx after JAWS II/TAg+X63/IL-2 cells. In
turn, the combined cell vaccines containing trans-
duced tumor cells caused a more intensive influx of
CD8+ lymphocytes than JAWS II/TAg+JAWS II/IL-2
cells.
Our results demonstrate that the most intensive
influx of both CD4+ and CD8+ cells into tumor tissue
was observed when IL-2-producing DCs or, alterna-
tively, TAg-stimulated DCs along with IL-2-secret-
ing syngeneic tumor cells, were delivered into the tu-
mor surroundings. Moreover, when both CD4+ and
CD8+ lymphocytes appeared in tumor tissue at a high
level, a positive correlation between the intensity of
the lymphocyte influx and the inhibition of the tumor
growth could be observed. As observed by Bos [12],
CD4+ cells presented in tumor tissue could help in
overcoming the immune tolerance by promoting the
CD8+ cell recruitment and activation of their cytolyt-
ic function together with the enhancement of the ef-
fector and memory CD8+ cell survival. The applica-
tion of JAWS II/TAg+X63/IL-2 cell combination
caused an influx of CD8+ cells similar to the other
combined vaccines. Nevertheless, they elicited an un-
expected overall effect inducing a weaker inhibition
of MC38 tumor growth (the lowest TGI) and short-
ening the survival time of mice (data not shown). Pre-
sumably, this was a consequence of the simultaneous
presence, in the vicinity of a growing tumor, of the
TAg-stimulated DCs and allogeneic tumor cells. This
parallel reaction directed towards two types of tumor
cells probably caused an arrest of tumor growth de-
lay. Thus, the application of allogeneic X63/IL-2 cells
alone caused more effective tumor growth delay than
the application of JAWS II/TAg+X63/IL-2 cell com-
bination despite the level of CD8+ lymphocyte infil-
tration increasing after the latter vaccination. The
application of vaccines of various origins seemed to
be able to polarize the antitumor response by exoge-
nous IL-2 and the encountered tumor antigen. This
could result in a division of tumor infiltrating CD8+
or CD4+ lymphocyte, down-regulated by tumor mi-
croenvironment.
To answer the question as to whether an increase
in the number of infiltrating cells would be associat-
ed with the level of lymphoid cell cytotoxicity, the
splenocytes obtained from the treated mice were in
vitro co-cultivated with MC38/0 tumor cells. Cytolitic
activity of splenocyte seemed to positively correlate
with the level of CD8+ lymphocyte infiltration of tu-
mor tissue (Figure 2). Furthermore, the application
of IL-2-producing cells and the increase in the CD4+
cell influx indicates the direct influence of IL-2 on
the activity of these lymphocytes.
This drew our attention to the complex relation-
ship between type of vaccine cells, cytokine produced
by them, level of infiltration of immune cells into
tumor tissue, and tumor ability to produce immun-
osuppressive cytokine such as TGF-b (data not
shown).
Hence, we hypothesize that differences in the de-
lay of tumor growth are a consequence of various
immune cell inductions resulting in the polarization
of the final antitumor response.
Figure 3. Cytotoxicity of restimulated spleen cells. Spleen
cells were co-cultured with mitomycin C treated MC38/0
cells for five days. After this time (restimulation), splenocy-
tes were co-cultured with target MC38 cells stained with
DiO (MC38/DiO). Next, MC38/0-DiO cells were stained
with PI and analyzed using flow cytometry. Cytotoxic index
was determined by the percentage of dead (PI-positive)
cells among MC38/0-DiO cells
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